Press release
Polycythemia Vera Market Set for Significant Growth Across 7MM Driven by Innovative Therapies and Rising Prevalence | DelveInsight
The 7MM Polycythemia Vera market size reached ~USD 1,900 million in 2024 and is projected to grow significantly through 2034. Key players such as Incyte/Novartis, PharmaEssentia/AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck (Imago BioSciences), Italfarmaco, Ionis Pharmaceutical, Silence Therapeutics, Perseus Proteomics, AbbVie, Johnson & Johnson Innovative Medicine, Mabwell (Shanghai) Bioscience and Disc Medicine, GluBio Therapeutics, and others are spearheading innovations in treatment approaches, addressing critical unmet needs in managing this chronic myeloproliferative neoplasm.
DelveInsight's report, titled "Polycythemia Vera Market Insight, Epidemiology and Market Forecast -2034 [https://www.delveinsight.com/report-store/polycythemia-vera-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]", provides a detailed assessment of historical and projected market trends from 2020 to 2034. The analysis encompasses epidemiology segmentation, treatment paradigms, emerging therapies, and competitive dynamics, offering stakeholders actionable insights into market opportunities and challenges. The report highlights how the anticipated introduction of targeted therapies and improved diagnostic tools will reshape the PV treatment landscape over the next decade.
In 2024, the United States dominated the Polycythemia market, accounting for over 75% of the total market size, which amounts to USD 1.9 Billion across the 7MM. Among EU4 countries, Germany accounts for the maximum market size, while the United Kingdom occupies the bottom of the ladder in 2024. This trend is expected to continue reflecting disparities in treatment accessibility, Polycythemia Vera prevalence, and diagnostic rates across regions.
Download the report to understand which factors are driving the Polycythemia Vera therapeutic market @ Polycythemia Vera Market Trends [https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
The report also provides historical as well as forecasted PV epidemiology segmented by Total Prevalent Population of Polycythemia Vera, Prevalent Population of Polycythemia Vera Based on Symptoms, Gender-specific Prevalence of Polycythemia Vera, Prevalence of Polycythemia Vera by Gene Mutation, Prevalence of Polycythemia Vera Based on Risk, and Age-specific Prevalence of Polycythemia Vera in the 7MM.
The report estimates that the 7MM had approximately 320,000 Polycythemia Vera cases in 2024, with numbers expected to rise steadily during the forecast period. Gender-specific data indicates that approximately 56% of the patient share in 7MM is attributed to males, whereas 44% are females. Additionally, across all races and ethnicities, the PV incidence is about 2.8 per 100,000 men and roughly 1.3 per 100,000 women.
Discover evolving trends in Polycythemia Vera patient pool forecasts @ Polycythemia Vera Epidemiology Analysis [https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Polycythemia Vera management currently relies on a combination of treatments, including phlebotomy, cytoreductive agents such as hydroxyurea, and JAK inhibitors like JAKAFI (RUXOLITINIB) from Incyte/Novartis. Other notable medications used in the management of PV include BESREMi (PharmaEssentia/AOP Orphan Pharmaceuticals) and PEGASYS (pharmaand GmbH). Given its very different MoA compared to JAKAFI and BESREMi, rusfertide could become a viable alternative as an earlier line of therapy. In 2024, JAKAFI generated the highest revenue among these Polycythemia Vera therapies.
While these therapies help manage symptoms and reduce thrombotic risks, they are associated with limitations including drug resistance, long-term toxicity, and inadequate control of disease progression. DelveInsight's report emphasizes that a significant number of patients experience suboptimal responses to existing treatments, highlighting a pressing need for novel mechanisms of action.
The report highlights that the Polycythemia Vera pipeline features several investigational therapies across phases of development. Notable candidates include DIVESIRAN (Silence Therapeutics), PPMX-T003 (Perseus Proteomics), NAVITOCLAX (AbbVie), VAC85135 (Johnson & Johnson), 9MW3011/DISC-3405 (Mabwell), GLB-001 (GluBio Therapeutic) and others .
Unlock which emerging Polycythemia Vera drug is expected to capture the largest market share in 7MM by 2034. Visit the Polycythemia Vera Market Insights [https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
In the latest financial statement, Incyte reported strong growth for Jakafi with net revenues of $773 million in Q4 2024 and $2.79 billion for the full year. In March 2025, Protagonist Therapeutics and Takeda announced positive topline results from the Phase 3 VERIFY study, where rusfertide met its primary and all secondary endpoints in treating polycythemia vera. These recent developments indicate positive momentum in the Polycythemia Vera treatment market.
Despite progress, challenges such as delayed diagnosis, treatment-related anemia, and lack of consensus on optimal monitoring strategies persist. DelveInsight's analysis identifies biomarker development and patient-centric drug delivery systems as key areas for innovation.
Table of Contents
1.
Key Insights
2.
Report Introduction
3.
Executive Summary
4.
Polycythemia Vera Market Overview at a Glance
5.
Epidemiology and Market Forecast Methodology
6.
Key Events
7.
Polycythemia Vera Background and Overview
8.
Polycythemia Vera Treatment
9.
Polycythemia Vera Epidemiology and Patient Population in the 7MM
10.
Polycythemia Vera Patient Journey
11.
Polycythemia Vera Marketed Drug
12.
Polycythemia Vera Emerging Drugs
13.
Polycythemia Vera: 7MM Analysis
14.
Unmet needs
15.
SWOT Analysis
16.
KOL Views
17.
Market Access and Reimbursement
18.
Appendix
19.
DelveInsight Capabilities
20.
Disclaimer
21.
About DelveInsight
Related Reports
Polycythemia Vera Pipeline Insight [https://www.delveinsight.com/report-store/polycythemia-vera-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Polycythemia Vera Pipeline Insight provides comprehensive insights about the Polycythemia Vera pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Polycythemia Vera companies, including Silence Therapeutics, Ionis Pharmaceuticals, Perseus Proteomics, Kartos Therapeutics, and Disc Medicine among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=polycythemia-vera-market-set-for-significant-growth-across-7mm-driven-by-innovative-therapies-and-rising-prevalence-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Polycythemia Vera Market Set for Significant Growth Across 7MM Driven by Innovative Therapies and Rising Prevalence | DelveInsight here
News-ID: 3915435 • Views: …
More Releases from ABNewswire
Nanocellulose Market Report 2025: Detailed Insights Into Market Trends, Projecti …
The nanocellulose market is poised for significant growth, driven by its eco-friendly nature, rising demand in packaging, biomedical, and composites, and advancements in sustainable materials. However, high production costs and technical challenges may impact expansion. Innovation and investments will be key to market development.
The nanocellulose market is projected to grow from USD 0.6 billion in 2024 to USD 3.4 billion by 2032, at a CAGR of 23.7% from 2024 to…
Hydrazine Hydrate Market Emerging Trends in Industry Dynamics, Size Insights, Sh …
The hydrazine hydrate market is driven by rising demand for polymer foams and expanding applications in fuel cells. However, its toxic nature and environmental concerns pose challenges. Strict regulations may impact growth, but advancements in safer applications could open new opportunities for the market.
The hydrazine hydrate market size was USD 222 million in 2021 and is projected to reach USD 308 million by 2027, at a CAGR of 5.8% from…
Coated Fabrics Market 2025 Top Business Strategy, Growth Factors, Healthy CAGR w …
The coated fabrics market is set for steady growth, driven by rising demand in automotive, industrial, and protective applications. Advancements in coating technologies and eco-friendly materials further boost market potential. However, fluctuating raw material prices and environmental concerns may pose challenges to expansion.
global coated fabrics market size was USD 23.7 billion in 2022 and is projected to reach USD 29.8 billion by 2028, at a CAGR of 3.9% from 2023…
AI Inference Market worth $254.98 Billion by 2030, at a CAGR of 19.2%
The global AI Inference Market is expected to grow from USD 106.15 billion in 2025 to USD 254.98 billion by 2030 at a CAGR of 19.2% during the estimated period 2025-2030.
The report "AI Inference Market [https://www.marketsandmarkets.com/Market-Reports/ai-inference-market-189921964.html?utm_source=abnewswire.com&utm_medium=PaidPR&utm_campaign=aiinferencemarket] by Compute (GPU, CPU, FPGA), Memory (DDR, HBM), Network (NIC/Network Adapters, Interconnect), Deployment (On-premises, Cloud, Edge), Application (Generative AI, Machine Learning, NLP, Computer Vision) - Global Forecast to 2030" The AI Inference market is…
More Releases for Polycythemia
Polycythemia Vera Therapeutics Market to See Incredible Growth During 2021 – 2 …
Polycythemia Vera Therapeutics Market is estimated to be valued at US$ 1,115.9 million in 2021 and is expected to exhibit a CAGR of +4% over the forecast period (2021-2029).
Polycythemia vera is a rare, chronic disorder involving the overproduction of blood cells in the bone marrow (myeloproliferation). The overproduction of red blood cells is most changing, but the production of white blood cells and platelets are also elevated in most cases.…
Post-Polycythemia Vera Myelofibrosis-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H2 2018, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline landscape.
Post-Polycythemia Vera Myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. It may also result in the overproduction of white blood cells and platelets. Symptoms include heart attack, stroke, deep venous thrombosis, Headaches, lack of…
Polycythemia Vera Pharmaceutical and Healthcare Pipeline Review H1
Summary
Polycythemia Vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness and excessive sweating. The risk of polycythemia vera increases with age. Treatment includes alkylating agents.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Polycythemia Vera - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Polycythemia Vera (Oncology), complete with analysis by stage of development,…
Develop business strategies Of Polycythemia Vera - Pipeline Review, H1 2018
"The Report Polycythemia Vera - Pipeline Review, H1 2018 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Polycythemia Vera Market
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Pipeline Review, H1 2018, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape.
Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/1581041
Polycythemia Vera (PV) is a stem…
Polycythemia Vera - Pipeline Review, H2 2017
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Pipeline Review, H2 2017, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape.
Polycythemia Vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness and excessive sweating. The risk of polycythemia vera increases with age. Treatment includes alkylating agents.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare…
Post-Polycythemia Vera Myelofibrosis Market - Pipeline Review, H2 2017
"The Latest Research Report Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Post-Polycythemia Vera Myelofibrosis Market
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H2 2017, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline landscape.
Post-Polycythemia Vera Myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which…
